Everolimus Versus Placebo in Head and Neck Cancer

Inclusion Criteria: * Diagnosis of Squamous cell carcinoma of the head and neck (stage IVa or IVb). No evidence (absence)of disease by scan. * 18 years or older. * Performance status 70% or better. * Adequate marrow, renal and liver function (will be tested by labs). \_ Able give consent. Exclusion Criteria: * Currently receiving anti-cancer treatment. * Major surgery or traumatic injury within 4 weeks. * Radiotherapy related toxicities. * Lip, nasopharynx, nasal cavity, paranasal sinus, salivary gland, skin, or thyroid primary tumors * Receiving other investigational drugs. * Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. * Receive immunization with attenuated live vaccines (seasonal flu shot)1 week before starting this . * Show evidence of disease (cancer). * Uncontrolled medical conditions such as: unstable angina, congestive heart failure, diabetes, severely impaired lung function. * Liver disease such as cirrhosis, severe hepatic impairment, Hepatitis B or C. * Active, uncontrolled severe infections * Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin. * Known History of HIV positivity. * Impaired gastrointestinal function that may alter absorption of Everolimus such as ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection. * Patients with an active, bleeding diathesis. * Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. ) * Male patient whose sexual partner(s) are Women of child bearing potential who are not willing to use adequate. contraception, during the study and for 8 weeks after the end of treatment * Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus). * Patients with a known hypersensitivity to Everolimus or other rapamycin analogues (sirolimus, temsirolimus) or to its excipients. * History of noncompliance to medical regimens. * Patients unwilling to or unable to comply with the protocol.